344 related articles for article (PubMed ID: 33482181)
1. A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.
Tarighi P; Eftekhari S; Chizari M; Sabernavaei M; Jafari D; Mirzabeigi P
Eur J Pharmacol; 2021 Mar; 895():173890. PubMed ID: 33482181
[TBL] [Abstract][Full Text] [Related]
2. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.
Xu J; Xue Y; Zhou R; Shi PY; Li H; Zhou J
Med Res Rev; 2021 May; 41(3):1375-1426. PubMed ID: 33277927
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 drug discovery and treatment options.
Chan JF; Yuan S; Chu H; Sridhar S; Yuen KY
Nat Rev Microbiol; 2024 Jul; 22(7):391-407. PubMed ID: 38622352
[TBL] [Abstract][Full Text] [Related]
4. New Hopes for Drugs against COVID-19 Come from the Sea.
Taglialatela-Scafati O
Mar Drugs; 2021 Feb; 19(2):. PubMed ID: 33670191
[TBL] [Abstract][Full Text] [Related]
5. A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials.
Mongia A; Saha SK; Chouzenoux E; Majumdar A
Sci Rep; 2021 Apr; 11(1):9047. PubMed ID: 33907209
[TBL] [Abstract][Full Text] [Related]
6. What Next? New Drugs, Old Drugs, and New Challenges in Choosing Treatments for Covid-19.
Peltan ID; Brown SM
NEJM Evid; 2022 Sep; 1(9):EVIDe2200189. PubMed ID: 38319796
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19).
Schepler H; Wang X; Neufurth M; Wang S; Schröder HC; Müller WEG
Theranostics; 2021; 11(13):6193-6213. PubMed ID: 33995653
[No Abstract] [Full Text] [Related]
8. Adverse events associated with potential drugs for COVID-19: a case study from real-world data.
Jing Y; Diao L; Han L
Brief Bioinform; 2021 Mar; 22(2):1232-1238. PubMed ID: 33003194
[TBL] [Abstract][Full Text] [Related]
9. COVID-19: Characteristics and Therapeutics.
Chilamakuri R; Agarwal S
Cells; 2021 Jan; 10(2):. PubMed ID: 33494237
[TBL] [Abstract][Full Text] [Related]
10. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.
Chaccour C; Casellas A; Blanco-Di Matteo A; Pineda I; Fernandez-Montero A; Ruiz-Castillo P; Richardson MA; Rodríguez-Mateos M; Jordán-Iborra C; Brew J; Carmona-Torre F; Giráldez M; Laso E; Gabaldón-Figueira JC; Dobaño C; Moncunill G; Yuste JR; Del Pozo JL; Rabinovich NR; Schöning V; Hammann F; Reina G; Sadaba B; Fernández-Alonso M
EClinicalMedicine; 2021 Feb; 32():100720. PubMed ID: 33495752
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
Dabbous HM; Abd-Elsalam S; El-Sayed MH; Sherief AF; Ebeid FFS; El Ghafar MSA; Soliman S; Elbahnasawy M; Badawi R; Tageldin MA
Arch Virol; 2021 Mar; 166(3):949-954. PubMed ID: 33492523
[TBL] [Abstract][Full Text] [Related]
12. A Comprehensive Summary of the Knowledge on COVID-19 Treatment.
Peng Y; Tao H; Satyanarayanan SK; Jin K; Su H
Aging Dis; 2021 Feb; 12(1):155-191. PubMed ID: 33532135
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?
Egeli BH; Sparks JA; Kim AHJ; Liew JW
Best Pract Res Clin Rheumatol; 2021 Mar; 35(1):101658. PubMed ID: 33483287
[TBL] [Abstract][Full Text] [Related]
14. COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development.
Singh R; Kang A; Luo X; Jeyanathan M; Gillgrass A; Afkhami S; Xing Z
FASEB J; 2021 Mar; 35(3):e21409. PubMed ID: 33577115
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of bevacizumab in patients with severe Covid-19.
Pang J; Xu F; Aondio G; Li Y; Fumagalli A; Lu M; Valmadre G; Wei J; Bian Y; Canesi M; Damiani G; Zhang Y; Yu D; Chen J; Ji X; Sui W; Wang B; Wu S; Kovacs A; Revera M; Wang H; Jing X; Zhang Y; Chen Y; Cao Y
Nat Commun; 2021 Feb; 12(1):814. PubMed ID: 33547300
[TBL] [Abstract][Full Text] [Related]
16. An update to monoclonal antibody as therapeutic option against COVID-19.
Deb P; Molla MMA; Saif-Ur-Rahman KM
Biosaf Health; 2021 Apr; 3(2):87-91. PubMed ID: 33585808
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2: From the pathogenesis to potential anti-viral treatments.
Zarandi PK; Zinatizadeh MR; Zinatizadeh M; Yousefi MH; Rezaei N
Biomed Pharmacother; 2021 May; 137():111352. PubMed ID: 33550050
[TBL] [Abstract][Full Text] [Related]
18. COVID-19: An overview and a clinical update.
Krishnan A; Hamilton JP; Alqahtani SA; Woreta TA
World J Clin Cases; 2021 Jan; 9(1):8-23. PubMed ID: 33511168
[TBL] [Abstract][Full Text] [Related]
19. Sex Differences in Immunity: Implications for the Development of Novel Vaccines Against Emerging Pathogens.
Fathi A; Addo MM; Dahlke C
Front Immunol; 2020; 11():601170. PubMed ID: 33488596
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
